MRKMerck Sharp & Dohme LLCRunning, no new patients
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 747 (final count)
- Started
- Feb 25, 2021
- Main results expected
- Feb 2, 2026
- Fully finished
- Feb 11, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 34 months
Overall Survival (OS)
Measured over: Up to approximately 44 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · paperwork · other
old: null
new: null
details: {"sections":["armsInterventionsModule","eligibilityModule","identificationModule","referencesModule","statusModule"]}
Trial ID NCT04586231 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC